Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.

Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor ...

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with ...

AI presents clear benefits to our severely challenged healthcare systems—but how can we deliver a better future without an ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

U.S. pharma companies should pay rather more of their corporate income tax in the U.S.—and start producing more of their best drugs in the U.S. as well.

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

Wall Street's main indexes opened subdued on Monday as investors awaited Iran's possible response to U.S. airstrikes on its ...

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market.

Remote-sensing data and artificial intelligence are mapping the most heat-vulnerable buildings in cities like Delhi, in an ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...